AVEO Oncology is a commercial-stage, oncology-focused biopharmaceutical company committed to delivering medicines that provide a better life for patients with cancer. Founded in 2001 and headquartered in Boston, Massachusetts, AVEO markets FOTIVDA® (tivozanib) in the U.S. for the treatment of adult patients with relapsed or refractory advanced renal cell carcinoma. In January 2023, AVEO became a wholly owned subsidiary of LG Chem Life Sciences USA, Inc., and continues to operate under the AVEO Oncology name.
Create a free account to see funding visualizations and detailed round data.
Create Free AccountCreate a free account to see full funding history, valuations, and investor participation.
Create Free AccountCreate a free account to see which investors have funded this company.
Create Free Account